Wednesday, July 8, 2026

pharma · Rectal Cancer · Fanconi Anemia · RCKT

Rocket Pharmaceuticals

Rocket Pharmaceuticals is a pharma organization headquartered in Cranbury, USA. It trades on NYSE under ticker RCKT. Primary therapeutic focus areas include Rectal Cancer, Fanconi Anemia, Danon Disease, PKP2 Arrhythmogen

9 Cedarbrook Dr, Cranbury, New Jersey 08512, US HQ
2015 Founded
226 Employees
Public company Type
RCKT · NYSE Ticker
Company details
Status
Public
HQ
9 Cedarbrook Dr, Cranbury, New Jersey 08512, US
Founded
2015
Employees
226
Programs
11
Drugs
10
Patents
1
Clinical program

Xuebijing

Approved · small molecule · Pulmonary Disease, Chronic Obstructive

Xuebijing for Pulmonary Disease, Chronic Obstructive is a Approved program (small_molecule) at Rocket Pharmaceuticals B.V. with 1 ClinicalTrials.gov record(s).

← All Rocket Pharmaceuticals B.V. projects Approved small molecule active

Internal code WK-2016-HR-02

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Rocket Pharmaceuticals B.V.
Phase
Approved
Modality
small_molecule
Indication
Pulmonary Disease, Chronic Obstructive
Status
active
Trials
1

Clinical trials